Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 5Waldenstrom Macroglobulinemia 1Recurrence 1Precancerous Conditions 1Neoplasms, Plasma Cell 1Medulloblastoma 1Mastocytosis, Systemic 1Lymphoma, Mantle-Cell 1Liver Neoplasms 1Leukemia, Large Granular Lymphocytic 1Ependymoma 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 3ruxolitinib 2fludarabine phosphate 2fludarabine 2Methotrexate 2thymoglobulin 1siltuximab 1duvelisib 1cc-486 1calaspargase pegol 1blinatumomab 1Whole-Body Irradiation 1Valganciclovir 1Transplantation 1Thiotepa 1Therapeutics 1Thalidomide 1Tacrolimus 1Radiotherapy 1Prednisone 1Positron-Emission Tomography 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Mesna 1Melphalan 1Interleukin-6 1Ifosfamide 1Granulocyte Colony-Stimulating Factor 1Ganciclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Large Granular Lymphocytic × Thalidomide × 1 year × Clear all
NCT06530576 2025-11-18

Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Recruiting
48 enrolled
Other hematologic neoplasm

Leukemia, Large Granular Lymphocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡